ALKS Alkermes plc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1520262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.3%
TTM net income YoY-100.1%
TTM EPS YoY-100.5%
Revenue 3-yr CAGR3.3%
Net income 3-yr CAGR—
Margins
Gross margin82.9%
Operating margin3.7%
Net margin-0.0%
FCF margin13.0%
EBITDA margin8.3%
Returns
ROE-0.0%
ROA-0.0%
ROIC (approx.)1.7%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.80x
Current ratio2.42x
Interest coverage0.74x
Cash quality & payout
Operating cash flow / net income-692.27x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $480.13M | $496.01M | $392.91M | $384.55M | $394.19M | $390.66M | $306.51M | $429.99M |
| Cost of revenue | $94.22M | $98.11M | $61.58M | $46.21M | $51.59M | $49.46M | $49.20M | $62.12M |
| Gross profit | $385.91M | $397.90M | $331.33M | $338.34M | $342.59M | $341.20M | $257.31M | $367.87M |
| R&D expense | $121.12M | $112.92M | $103.34M | $93.04M | $81.74M | $77.37M | $71.82M | $58.17M |
| SG&A expense | $208.50M | $217.62M | $264.59M | $187.20M | $171.77M | $170.85M | $171.70M | $146.99M |
| Operating income | $36.02M | $18.35M | -$48.28M | $58.10M | $89.08M | $92.98M | $13.79M | $162.69M |
| Interest expense | $27.55M | $25.93M | $20.89M | $12.28M | $0 | $0 | $0 | $4.65M |
| Pretax income | $14.74M | -$1.88M | -$61.93M | $60.38M | $100.75M | $104.84M | $25.49M | $169.89M |
| Income tax | -$1.55M | -$2.38M | $4.55M | $11.04M | $17.98M | $17.74M | $3.02M | $24.15M |
| Net income | $16.29M | $501,000 | -$66.48M | $49.34M | $82.76M | $87.10M | $22.46M | $146.50M |
| EBITDA | $63.18M | $48.63M | -$28.85M | $61.95M | $97.16M | $100.80M | $21.21M | $169.53M |
| EPS (basic) | 0.10 | 0.00 | -0.40 | — | 0.50 | 0.53 | 0.14 | — |
| EPS (diluted) | 0.09 | 0.00 | -0.40 | — | 0.49 | 0.52 | 0.13 | — |
| Weighted avg. shares (diluted) | 176.37M | 173.48M | 166.20M | — | 168.51M | 168.36M | 168.74M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $631.31M | $511.53M | $351.55M | $388.57M | $616.45M | $521.20M | $399.81M | $291.15M |
| Short-term investments | $124.15M | $145.05M | $160.31M | $199.65M | $494.67M | $494.54M | $484.21M | $460.52M |
| Receivables | $459.09M | $456.48M | $407.63M | $334.02M | $354.39M | $354.91M | $318.70M | $384.53M |
| Inventory | $261.10M | $298.96M | $336.70M | $196.62M | $191.00M | $191.92M | $183.44M | $182.89M |
| Current assets | $1.58B | $1.52B | $1.36B | $1.93B | $1.74B | $1.64B | $1.48B | $1.42B |
| PP&E, net | $215.02M | $218.28M | $220.59M | $221.72M | $246.98M | $239.40M | $233.92M | $227.56M |
| Goodwill | $592.52M | $594.27M | $596.03M | $83.03M | — | — | — | $83.03M |
| Intangibles | $1.74B | $1.76B | $1.78B | $815,000 | — | — | — | $890,000 |
| Total assets | $4.44B | $4.39B | $4.26B | $2.49B | $2.33B | $2.25B | $2.08B | $2.06B |
| Current liabilities | $651.93M | $662.09M | $599.50M | $543.44M | $474.36M | $505.96M | $443.73M | $465.20M |
| Short-term debt | $26.50M | $26.50M | $26.50M | $0 | — | — | — | — |
| Long-term debt | $1.47B | $1.48B | $1.48B | $0 | — | — | — | — |
| Total debt | $1.50B | $1.50B | $1.51B | $0 | — | — | — | — |
| Total liabilities | $2.57B | $2.58B | $2.51B | $667.70M | $596.08M | $628.23M | $570.39M | $590.59M |
| Shareholders' equity | $1.86B | $1.81B | $1.75B | $1.82B | $1.73B | $1.62B | $1.51B | $1.46B |
| Net debt | $866.42M | $991.58M | $1.16B | -$388.57M | — | — | — | — |
| Shares outstanding | 168.03M | 167.54M | 166.46M | 165.61M | 165.10M | 165.05M | 164.85M | 162.18M |
| Cash flow statement | ||||||||
| Operating cash flow | $93.48M | $145.18M | -$165.74M | $170.07M | $101.67M | $150.20M | $98.81M | $190.40M |
| Capital expenditure | $3.40M | $8.15M | $4.09M | -$20,000 | $17.31M | $13.02M | $10.11M | $9.77M |
| Free cash flow | $90.08M | $137.04M | -$169.83M | $170.09M | $84.36M | $137.19M | $88.70M | $180.62M |
| Investing cash flow | $19.99M | -$2.41M | -$2.08B | $322.35M | -$6.74M | -$29.21M | $9.10M | -$13.88M |
| Financing cash flow | $6.32M | $17.20M | $1.47B | $10.91M | $315,000 | $405,000 | $747,000 | -$281.67M |
| Depreciation & amortization | $27.16M | $30.28M | $19.43M | $3.85M | $8.08M | $7.82M | $7.42M | $6.85M |
| Stock-based compensation | $26.75M | $31.14M | $36.33M | $26.27M | $24.66M | $24.97M | $22.81M | $20.75M |
| Share buybacks | $0 | $0 | $27.70M | — | $0 | — | — | $1,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.